Use of various humanized small animal models, where immunocompromised mice are reconstituted with either HSPCs or differentiated T-cells to confer susceptibility to HIV-1 infection, have facilitated preclinical assessments of in vivo efficacy of various CCR5-targeted HIV-1 therapies. Here, CCR5 is linked to HIV-1 infection.